HOME >> MEDICINE >> NEWS
Men with severe sleep breathing disorder have higher risk of heart problems

Men with a severe form of a sleep breathing disorder called obstructive sleep apnoea-hypopnoea have an increased risk of fatal and non-fatal cardiovascular events, concludes a study published in this week's issue of THE LANCET.

Obstructive sleep apnoea-hypopnoea affects four per cent of middle-aged men and two per cent of middle-aged women. It is caused by a blockage in the pharynx that obstructs airflow during sleep. Individuals with the condition regularly stop breathing during sleep for 10 seconds or longer (apnoea) and have slowed breathing (hypopnoea). It is associated with high rates of illness and mortality. Previous studies have linked it with an increased risk of cardiovascular disease but these have not taken into account potential confounding factors. After adjustment for age and obesity such studies have not been able to show an increased risk.

Jose Marin (Hospital Universitario Miguel Servet, Spain) and colleagues recruited 264 healthy men matched for age and body mass index, 377 simple snorers, 403 with untreated severe disease and 372 with the disease and treated with continuous positive airway pressure (CPAP). Participants were followed-up at least once a year for an average of 10 years. Patients with untreated severe disease had a higher incidence of fatal cardiovascular events (1.06 per 100 person-years) and non-fatal cardiovascular events (2.13 per 100 person-years) than untreated patients with mild-moderate disease, simple snorers, patients treated with CPAP and healthy participants-- even after adjustment for potential confounding factors.

Dr Marin concludes: "The results of this large, long-term, prospective controlled study suggest that in untreated men with severe obstructive sleep apnoea-hypopnoea, the risk of fatal and non-fatal cardiovascular events is increased. There is a relation between the severity of this disease and cardiovascular risk, but effective treatment with nasal CPAP significantly reduces the cardi
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
17-Mar-2005


Page: 1 2

Related medicine news :

1. New generation contact lenses cut risk of severe eye infection
2. Teen athletes continue tobacco use, despite severe consequences
3. Two years after gene therapy treatments, severe angina patients showed prolonged clinical benefit
4. Emory Study finds HIV is not an independent risk factor for severe heart disease
5. Study shows long-term use of NSAIDs causes severe intestinal damage
6. Patients with moderate or severe hand dermatitis responsive to drug therapy
7. Prialt receives positive CHMP recommendation for intrathecal treatment of severe chronic pain
8. Smoking cessation can improve survival among patients with severe COPD
9. Patients with severe depression improve using guidelines developed by UT Southwestern researchers
10. NIH launches study of hematopoietic stem cell transplantation for severe, treatment-resistant lupus
11. Rectal artesunate could be initial treatment option for moderate to severe malaria

Post Your Comments:
(Date:5/21/2013)... (PRWEB) May 21, 2013 DISCcert has ... showing how to use 17 DISC applications at the ... a natural progression. , The July 25 & 26th ... top 17 ways of applying DISC. The time-tested, proven ... graduates. The user-friendly DISC training materials ; ...
(Date:5/21/2013)... New York, New York (PRWEB) May 21, 2013 ... dedicated to protecting the rights of victims injured by ... the Journal of Bone & Joint Surgery on May ... (MRI) can be used to identify complications that occur ... have any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... stent, which is a novel stent platform eluting ... the Xience Prime everolimus-eluting stent for the primary ... nine months in the results of an imaging ... BIOFLOW-II substudy used intravascular ultrasound (IVUS) and optical ... and stent apposition at nine months after treating ...
(Date:5/21/2013)... 21, 2013 Phoseon Technology will present ... the 20th Annual IMI European Ink Jet Conference ... leader, Phoseon continues to invest in product development to ... of UV LED curing in printing applications. Phoseon ... the market offering both air cooled and water cooled ...
(Date:5/21/2013)... AURORA, Colo. (May 21, 2013) A paper recently ... and co-written by physicians and scientists at the ... important genetic risk factor for pulmonary fibrosis can be ... lung disease. , Researchers looked at a fairly common ... is a component of the mucous produced by the ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
(Date:5/21/2013)... 2013  Lehigh Valley Health Network has announced the ... adding to its existing arsenal of five 5-foot-5 germ-killing ... within the network, LVHN is now deploying the largest ... superbugs and provide the best possible patient care available. ... TRU-D – the signature product of Memphis ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May 21, ... and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that ... online the positive Phase 2a study results of dupilumab ... an investigational monoclonal antibody targeting the alpha subunit of ... of both IL-4 and IL-13, drivers of Th2 (Type ...
(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2
Cached News: